A plain-English beginner's guide — what they are, the main types, how they're made and taken, safety, and the legal picture in Ireland. Full research library below.
Last updated: July 2026The same handful of questions come up every time someone finds out I research this stuff: what actually is a peptide, is it the same as a steroid, how is it taken, is it safe, and is it even legal here. This page answers all of that in plain English, once, properly. It's the beginner's version. If you are coming at this from the gym rather than the science, start with what peptides actually are, written for Irish gym-goers — the same ground in five minutes, including what gets sold online versus what the research supports. When you want the detail on a specific compound, that's what the full research library further down the page is for.
A peptide is a short chain of amino acids, the same building blocks your body uses to make every protein you're built from. String enough amino acids together and you get a protein; a shorter chain (roughly 50 amino acids or fewer) is called a peptide. That's the whole distinction. It's length, not some exotic separate class of chemical.
Your body already makes thousands of peptides on its own, and it uses them as signals. Different peptides carry instructions for different jobs, including:
Therapeutic or "research" peptides are lab-made versions designed to copy or support one of those natural signals. That's why they sit much closer to hormones than to steroids, and it's worth being clear on that early, because the two get lumped together constantly and they don't work the same way.
They work as signals, not as fuel. A peptide binds to a receptor on a cell, the receptor passes a message inside, and the cell does something differently — releases a hormone, starts repairing, changes how it handles energy. That is the whole mechanism, and it is why peptides sit closer to hormones than to steroids.
Two things follow from that. First, a peptide can only do something your body already has the machinery to do; it turns up a signal that already exists rather than adding a new one. Second, the receptor decides the effect, not the compound’s reputation. Ipamorelin and GHRP-6 both act at the same growth hormone receptor, but GHRP-6 drives appetite hard and Ipamorelin barely touches it. Same family, different result.
Peptides aren't one thing with one effect. They're usually grouped by the outcome researchers are interested in. Here's the plain-English map, with an example compound or two for each. Where there's a full guide in the library below, the name links to it.
| What it's studied for | Example peptides |
|---|---|
| Weight loss & metabolic health | Semaglutide, Tirzepatide |
| Muscle growth & recovery | Sermorelin, Ipamorelin, CJC-1295 |
| Longevity & cellular energy | Epitalon, MOTS-c |
| Inflammation & healing | BPC-157, TB-500, collagen peptides |
| Sleep | DSIP (delta sleep-inducing peptide) |
| Cognitive & focus | Selank, Semax |
| Immune support | Thymosin alpha-1 |
| Skin & collagen | GHK-Cu, collagen peptides |
| Sexual function | PT-141, Oxytocin |
One honest caveat: the strength of the evidence is very different across that table. Semaglutide and tirzepatide have large human trials behind them. A lot of the recovery, longevity and cognitive compounds are backed mostly by animal studies and early-stage work. Don't assume a fact about one peptide applies to another just because they're both "peptides". Read the individual guide before you draw conclusions.
GHK-Cu is the one with genuine independent research behind it. It is a copper-binding tripeptide the body already makes, studied for collagen production, wound healing and gene expression, and it appears in cosmetic formulations as Copper Tripeptide-1. AHK-Cu is its close relative with far thinner evidence — most of what is known comes from a single hair-follicle study.
Collagen peptides are the odd one out: taken orally, absorbed well, and the only peptide in this section most people will ever buy in a shop.
One distinction worth holding on to: most of the GHK-Cu literature is topical or in cell culture. Applying something to skin and injecting it are not the same question.
Honestly, none of them have convincing human evidence for building muscle in healthy trained people.
The growth-hormone-axis compounds — Ipamorelin, Sermorelin, CJC-1295, the GHRPs, MK-677 — do reliably raise growth hormone and IGF-1. That part is measured and not in dispute. Whether raising those numbers in an already-healthy adult produces meaningful extra muscle is a different question, and the answer is much less flattering. MK-677 has a two-year trial in older adults that raised IGF-1 and maintained lean mass, and reported no improvement in functional measures.
Follistatin 344 is sold on myostatin inhibition, but the human data comes from gene therapy trials rather than the injectable protein. MGF and PEG-MGF rest on splice-variant biology observed in rodents.
The SARMs get asked about in the same breath and belong in a separate box: they act on the androgen receptor, not the GH axis, and MK-677 is filed with them everywhere despite not being one. RAD-140 is the most marketed of them and has no randomised performance trial at all — its only human study was a phase 1 in cancer patients, and its main finding was liver enzyme elevation. See the full SARMs page and the HardCore Supplements review for where this is actually sold in Ireland and what the disclosure says.
The boring answer is still the true one. A calorie surplus, enough protein and progressive overload do more than any of this, and they cost nothing.
Worth understanding, because it partly explains why sourcing quality matters so much. Peptides used in research and medicine come from three broad routes:
| Type | How it's made | Examples |
|---|---|---|
| Bioactive | Released from natural food proteins, or occurring naturally in the body | Collagen peptides, GHK-Cu |
| Synthetic | Built chemically, amino acid by amino acid, in a lab (generally chains of 50 amino acids or fewer) | Semaglutide, tirzepatide, tesamorelin |
| Recombinant | Produced using DNA technology — cells are engineered to manufacture it — used for longer chains (more than 50 amino acids) | Human growth hormone, insulin |
The method itself isn't really the risk. A peptide can be made perfectly and still be a gamble if it's then handled by an unregulated supplier with no real quality control. Purity is the thing that actually matters, and I'll come back to that under safety.
Most peptides are given by subcutaneous injection — a small injection into the fat layer just under the skin. The reason is simple: peptides are proteins, and the digestive system breaks proteins down, so swallowing most of them doesn't work. Oral bioavailability (how much actually makes it into your bloodstream) is often only around 1–2%. Collagen peptides are the notable exception, absorbing at roughly 63% orally, which is why collagen is one of the few you'll genuinely see sold as a powder or capsule.
Injectable peptides usually arrive as a freeze-dried powder that has to be reconstituted (mixed into liquid) before use. The general handling principles researchers follow:
The full step-by-step version — bacteriostatic water versus sterile water, equipment, storage, and the mistakes beginners make — is in the peptide reconstitution guide.
This site does not publish dose, volume, or syringe-draw calculations for any compound — that's a conversation for a pharmacist or doctor, not a fitness website.
The honest version, not the sales-page version. A few things are worth understanding before anyone goes near this:
None of the above is a green light. It's context. If you're seriously considering anything here, the sensible order is bloodwork and a conversation with a doctor first, purchase later — not the other way around. I had that order wrong for years myself; why I test before I change anything now is the short version of why I stopped guessing. Speak to a qualified healthcare professional who knows your history before making any decision.
It depends entirely on which peptide, and for a lot of them nobody knows, because the human safety data does not exist. Where side effects are documented, these are the ones that come up repeatedly:
Melanotan II deserves naming on its own. It has no approval from any medicines regulator anywhere, and the documented concerns include new or changing moles and pigmented lesions, priapism, and case reports of acute kidney injury from unregulated injectable use.
And the risk nobody puts on a list: what is actually in the vial. With unregulated suppliers, contamination and inaccurate content are more likely to cause harm than the peptide’s own pharmacology.
This is more complicated than a yes/no, and I'm not a solicitor, so treat this as context rather than legal advice. The picture splits roughly in two:
A word of caution that follows directly from that: because those research-grade compounds aren't regulated as medicines, purity and quality control can be genuinely poor. There's no regulator checking that what's on the label is what's in the vial. That's the single biggest practical risk with unapproved peptides, and it's worth weighing heavily.
(You'll sometimes see American sources describe peptide regulation in terms of the FDA and "503A/503B" compounding pharmacies. That's US law and it doesn't apply in Ireland — here the relevant body is the HPRA.)
Peptides are one of the faster-moving areas in health research right now. The GLP-1 category alone has gone from a diabetes treatment to one of the most significant weight-loss developments in decades, and newer multi-receptor compounds are still working through clinical trials. Beyond metabolism, there's active research into peptides for recovery, immune support and age-related decline — though a lot of that is still early, and early research has a habit of looking more certain in a headline than it does in the data.
The honest summary: it's a genuinely promising field, the tools for delivery and design keep improving, and it's also one where the hype runs well ahead of the evidence for most compounds. The useful move as a beginner isn't to chase the newest thing — it's to understand the fundamentals (like the ones on this page), get your basics right first, and read the actual research on anything specific before acting.
Ready to go deeper? Below is every peptide compound and GLP-1 covered on No Nonsense Fitness, grouped by category. Each card links to a full research guide covering mechanism, the published data, relevant stacks, side-effect profile, and Irish regulatory context. All free, no sign-up.
GLP-1 receptor agonists, multi-receptor agonists, and fat-loss peptides studied for metabolic health and body composition. Includes approved medicines and compounds in clinical development.
Triple agonist (GLP-1 / GIP / Glucagon). Phase 2 trial: 24.2% weight loss at 48 weeks in the 12 mg arm — highest result published for any weight loss compound to date.
View Research →GLP-1 receptor agonist. STEP-1 trial: 14.9% weight loss at 68 weeks. Approved in Ireland for type 2 diabetes (Ozempic) and obesity (Wegovy).
View Research →Dual agonist (GLP-1 / GIP). SURMOUNT-1 trial: 22.5% weight loss at 72 weeks. Approved in Ireland for type 2 diabetes as Mounjaro.
View Research →Modified fragment of human growth hormone studied specifically for fat metabolism. Targets fat cell lipolysis without the growth-promoting effects of HGH.
View Research →C-terminal fragment of human growth hormone. Studied for selective fat-burning activity with no effect on blood glucose or insulin-like growth factor levels.
View Research →Long-acting amylin analogue. In combination trials with semaglutide (CagriSema), has shown >25% weight loss results. Currently in Phase 3 development.
View Research →Triple monoamine reuptake inhibitor studied for obesity. Phase 2 trials showed 10.6% weight loss at 24 weeks. Distinct mechanism from GLP-1 compounds.
View Research →GLP-1 / Glucagon dual agonist developed in China. Phase 3 trials ongoing. Targets both appetite reduction and energy expenditure via dual receptor activation.
View Research →Peptides studied for tissue regeneration, injury recovery, gut health, and wound healing. Research base largely preclinical; popular in sports science circles.
Studied for gut healing, tendon repair, and injury recovery. One of the most researched recovery peptides, with over 100 preclinical publications.
View Research →Tissue regeneration, wound healing, and flexibility research. Derived from a naturally occurring protein. Widely studied in recovery and anti-inflammatory research.
View Research →Copper peptide studied for collagen synthesis, skin repair, and wound healing. Also researched for anti-inflammatory and antioxidant properties.
View Research →Innate repair receptor agonist. Studied for neuropathic pain, anti-inflammatory effects, and tissue protection. Has entered clinical trials for diabetic neuropathy.
View Research →Tripeptide derived from alpha-MSH. Studied for potent anti-inflammatory effects, gut healing, and reduction of inflammatory bowel disease markers in preclinical models.
View Research →Human cathelicidin antimicrobial peptide. Studied for broad-spectrum antimicrobial activity, wound healing, and immune modulation. Naturally produced in skin and respiratory tissue.
View Research →IGF-1 splice variant released by muscle after mechanical loading. Studied for satellite cell activation, muscle repair, and recovery acceleration following resistance exercise.
View Research →Pegylated form of MGF engineered for extended half-life. Studied for muscle satellite cell activation; pegylated form has a much thinner published evidence base than native MGF.
View Research →Myostatin-binding protein and activin antagonist. Studied in animal models for muscle growth via myostatin inhibition; human injectable data is sparse.
View Research →Immune-modulating peptide derived from the thymus. Studied for T-cell activation, antiviral response, and immune system support. Approved in some countries for hepatitis B/C.
View Research →GHRPs and GHRH analogues studied for growth hormone release, lean mass, sleep quality, and recovery. Not approved medicines; research use only.
GHRP (growth hormone releasing peptide). Studied for GH pulse release, sleep quality improvement, and lean mass research. Considered selective with a low side effect profile in studies.
View Research →GHRH analogue. Growth hormone secretagogue studied for anti-aging effects, lean mass, and recovery. Shorter half-life than CJC-1295.
View Research →Oral GH secretagogue. Studied for lean mass, sleep quality, and IGF-1 elevation. Taken orally, not injected — unusual among GH-axis compounds.
View Research →Insulin-like Growth Factor 1. Key downstream mediator of GH signalling. Studied for muscle hypertrophy, recovery, and anabolic effects in preclinical research.
View Research →GHRH analogue with a shorter half-life than the DAC variant, preserving natural pulsatile GH release. Standalone research guide (see also the Ipamorelin stack guide below).
View Research →GHRH analogue combined with Ipamorelin for synergistic GH pulse release. Short half-life (no DAC variant) preserves natural pulsatile GH release. One of the most popular GH-axis stacks in research.
View Stack Guide →Second-generation growth hormone releasing peptide. Strong GH pulse stimulator studied for lean mass, appetite increase, and IGF-1 elevation. More potent ghrelin mimetic than GHRP-6.
View Research →First-generation growth hormone releasing peptide. Strong appetite stimulant alongside GH release. Widely used in research; often stacked with a GHRH analogue for synergy.
View Research →Synthetic GHRH analogue. FDA-approved for HIV-associated lipodystrophy; studied for visceral fat reduction, cognitive function, and GH deficiency. One of the better-evidenced GHRH compounds.
View Research →Recombinant human growth hormone. Approved medicine for GH deficiency and related conditions; off-label anti-ageing/bodybuilding use is not an approved indication anywhere.
View Research →Long R3 IGF-1 analogue with amino acid substitutions extending half-life versus native IGF-1. Studied for anabolic/hypertrophy research; largely grey-market human use data.
View Research →Peptides studied for cognitive enhancement, metabolic function, cellular energy, and longevity. Includes nootropic peptides and mitochondrial compounds.
Russian nootropic peptide derived from ACTH. Studied for BDNF upregulation, cognitive function, focus, and stress resilience. Used clinically in Russia for stroke recovery.
View Research →Anxiolytic peptide derived from tuftsin. Studied for anxiety reduction, cognitive focus, and immune modulation. Used clinically in Russia as an anti-anxiety compound.
View Research →Tetrapeptide studied for telomere elongation, longevity research, and pineal gland function. One of the most studied compounds in aging biology research.
View Research →Nicotinamide adenine dinucleotide. Essential coenzyme in cellular energy metabolism. Studied for mitochondrial function, DNA repair, and aging mechanisms.
View Research →Mitochondria-derived peptide. Studied for metabolic function, insulin sensitivity, and exercise performance. Encodes in mitochondrial DNA — a unique class of signalling peptide.
View Research →Mitochondria-derived peptide. Studied for cytoprotection, neuroprotection, insulin sensitivity, and age-related decline. Levels naturally decline with age in human studies.
View Research →Mitochondria-targeting antioxidant peptide. Studied for mitochondrial dysfunction, cardioprotection, and age-related energy decline. Targets the inner mitochondrial membrane directly.
View Research →Endogenous neuropeptide studied for sleep regulation, stress resilience, and hormone modulation. Isolated from rabbit cerebral blood during sleep — one of the earliest identified sleep peptides.
View Research →NNMT inhibitor studied for fat cell metabolism, energy expenditure, and weight management. Targets the nicotinamide N-methyltransferase pathway involved in obesity and metabolic disease.
View Research →AMPK activator studied as an exercise mimetic. Preclinical research showed improved endurance and fat oxidation without exercise. Acts on the same energy-sensing pathway activated by physical training.
View Research →Senolytic peptide that disrupts the FOXO4-p53 interaction in senescent cells. Built on a landmark 2017 Cell paper; preclinical only, no human trials.
View Research →Endogenous tripeptide antioxidant. Substantial real clinical evidence base for oxidative stress and liver detoxification contexts; also used off-label for skin brightening.
View Research →Neural cell adhesion molecule (NCAM) mimetic peptide. Studied for memory and synaptic plasticity in preclinical/animal models; essentially no human data.
View Research →PKC epsilon activator studied for memory and cognitive enhancement in Alzheimer's-model research. Preclinical only.
View Research →Spadin-derived peptide fragment; TREK-1 potassium channel blocker studied for antidepressant effects in rodent models. Preclinical only, thin published evidence base.
View Research →Compounds spanning reproductive endocrinology, pigmentation, appetite, and metabolic signalling that don't fit the categories above. Mix of approved medicines and research-only compounds.
Melanocortin receptor (MC4R) agonist. FDA-approved as Vyleesi for hypoactive sexual desire disorder in the US; not approved in Ireland/EU.
View Research →KISS1R agonist regulating the hypothalamic-pituitary-gonadal axis. Substantial human trial base (Imperial College London) despite no regulatory approval.
View Research →Alpha-MSH analogue. FDA/EMA-approved as Scenesse for erythropoietic protoporphyria photoprotection, with real regulatory history distinct from grey-market use.
View Research →Non-selective melanocortin agonist studied for tanning and libido effects. Not approved anywhere; documented safety concerns with unregulated grey-market use.
View Research →Human Chorionic Gonadotropin. Approved medicine for fertility and hypogonadotropic hypogonadism; also used off-label in TRT protocols for testicular function preservation.
View Research →Neuropeptide hormone. Approved medicine for labour induction/postpartum haemorrhage; extensive separate research literature on social bonding, trust, and anxiety.
View Research →Non-steroidal topical antiandrogen studied for androgenetic alopecia. Local androgen receptor antagonism at the scalp — development discontinued, no completed human trials.
View Research →Pairs a local antiandrogen (RU58841) with a tissue-support copper peptide (GHK-Cu) — hormonal driver and follicle environment addressed separately. Research overview, not a documented personal protocol.
View Stack Guide →Copper tripeptide related to GHK-Cu, studied for dermal papilla proliferation and hair follicle elongation. Evidence base is a single ex vivo/in vitro study, far thinner than GHK-Cu's.
View Research →Synthetic ERR agonist "exercise mimetic" (a small molecule, not a peptide). Saint Louis University research; mouse-only endurance/metabolism data.
View Research →* Retatrutide 48-week figure is from Phase 2 data. Phase 3 results pending. All trial results are at highest studied doses in placebo-controlled trials.
| Compound | Receptors | Best Trial Result | Trial Duration | Status (Ireland) |
|---|---|---|---|---|
| Semaglutide | GLP-1 | 14.9% weight loss | 68 weeks | Approved (T2D) |
| Tirzepatide | GLP-1 + GIP | 22.5% weight loss | 72 weeks | Approved (T2D) |
| Retatrutide | GLP-1 + GIP + Glucagon | 24.2% weight loss* | 48 weeks* | Phase 3 |
Dosing and cycle calculators are right here on this page (above). For the nutrition side — macros, calories, food tracking — the free tools have you covered.
Free Tools Read the Blog